Aurobindo Pharma

Hyderabad, India Founded: 1986 • Age: 40 yrs Listed Fortune India 500 · #87
Generic biocatalytic solutions are provided for pharmaceutical applications.
Request Access
Report Incorrect Data
Page last updated

About Aurobindo Pharma

Aurobindo Pharma is a publicly listed company based in Hyderabad (India) founded in 1986 by P V Ramprasad Reddy and K Nityananda Reddy. Generic biocatalytic solutions are provided for pharmaceutical applications. The company has 40,750 employees. Aurobindo Pharma has completed 8 acquisitions, including Advent Pharma, GLS Pharma and Generis Farmaceutica. Its chief executive, as recorded, is Sanjay Chaturvedi. Its website aurobindo.com draws about 24 thousand monthly visits. Its Indian entity Aurobindo Pharma Ltd reported revenue of ₹34,147 Cr. Aurobindo Pharma offers products and services including APIs, Biosimilars, and Speciality Products. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Diversified Pharmaceuticals. Its competitors include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals; 1 of its 3 listed competitors has raised funding.

Company details

Aurobindo Pharma was founded in 1986 in Hyderabad, India, and operates within the pharmaceutical sector. Generic drugs and biocatalytic solutions are developed and manufactured by the company, with a focus on active pharmaceutical ingredients and formulations. Operations are conducted globally, serving markets in over 150 countries through exports and partnerships. Leadership is provided by co-founders P V Ramprasad Reddy and K Nityananda Reddy, alongside CEO Sanjay Chaturvedi.

Aurobindo Pharma is ranked #87 on the Fortune India 500 (2025).

Recognitions & Rankings of Aurobindo Pharma

Fortune India 500 2025 edition
Rank#87
Total income
₹32,943 Cr
Profit
₹3,486 Cr
Last year #80
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#92
Valuation
₹72,630 Cr
2023 #91 2022 #132 2021 #101
  • Headquarters Hyderabad, India
  • Employees 40,750
  • Founders P V Ramprasad Reddy, K Nityananda Reddy
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website aurobindo.com
  • Social LinkedIn X Facebook
  • Legal Name Aurobindo Pharma Ltd
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹1,06,750 Cr

    AUROPHARMA · NSE

  • Share Price
    ₹1,855.30

    +2.84% today

  • Revenue
    ₹33,653 Cr

    FY 2025-26 · +6.1% YoY

  • EBITDA
    ₹6,780 Cr

    Margin 20.1%

  • Net Profit
    ₹3,563 Cr

    FY 2025-26 · +3.2% YoY

  • P/E (TTM)
    25.6x

    P/B 2.6x

  • ROE
    9.9%

    ROCE 12.4%

  • Debt / Equity
    0.23

    Interest cover 7.7x

  • Investors
    Gates Foundation

    & 1 more

  • Employee Count
    40,750
  • Investments & Acquisitions
    Advent Pharma

    & 7 more

Products & Services of Aurobindo Pharma

Aurobindo Pharma offers a comprehensive portfolio of products and services, including APIs, Biosimilars, and Speciality Products.

APIs
Active Pharmaceutical Ingredients

Raw materials used in drug manufacturing for global markets.

Biosimilars
Biologic Drugs

Generic biologics targeting oncology and immunology therapies.

Speciality Products
Pharmaceutical Formulations

Advanced drugs for specific therapeutic needs worldwide.

Funding Insights of Aurobindo Pharma

  • Total Rounds 3
  • First Round $6.2M

    (Sep 1999)

  • Investors Count 2

All 3 funding rounds of Aurobindo Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2017Post-IPO––
Gates Foundation
Apr 2011Post-IPO––
Templeton Private Equity Partners
Sep 1999$6.2MPost-IPO––
–
Valuation history

2 investors in total: 2 institutional.

Investors in Aurobindo Pharma

Aurobindo Pharma has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation and Templeton Private Equity Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Templeton Private Equity Partners
Global private equity investments are managed by the firm.
templetonpe.comSingapore, Singapore
Gates Foundation
Charitable foundation investments on poverty reduction and healthcare
2000gatesfoundation.orgSeattle, United States
Premium access

Investor details for Aurobindo Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Aurobindo Pharma Ltd (Aurobindo Pharma)

Aurobindo Pharma Ltd is the primary company behind Aurobindo Pharma. The boards of the 6 registered companies of Aurobindo Pharma currently have 19 directors; the longest-serving is Venkata Ramprasad Reddy Penaka, appointed in 1992. 57 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Venkata Ramprasad Reddy Penaka
DIN 01284132
Director30 Dec 199233 yrs 10 moAurobindo Pharma Ltd
Nityananda Reddy Kambam
DIN 01284195
Director19 Dec 200619 yrs 10 moApl Healthcare Limited, Aurobindo Pharma Ltd, Aurozymes Limited, Silicon Life Sciences Private Limited
Sivakumaran Meenakshisunderam
DIN 01284320
Director19 Dec 200619 yrs 10 moApl Healthcare Limited, Curepro Parenterals Limited, Aurozymes Limited
Madan Mohan Reddy Mettu
DIN 01284266
Director21 Aug 201313 yrs 2 moCurepro Parenterals Limited, Aurobindo Pharma Ltd, Aurozest Private Limited
Sarath Chandra Reddy Penaka
DIN 01628013
Director12 Sep 201313 yrs 1 moCurepro Parenterals Limited, Aurobindo Pharma Ltd
Venkateswararao Kondreddy
DIN 02907769
Director28 Feb 20188 yrs 8 moSilicon Life Sciences Private Limited
Venkata Radhakrishna Racharla
DIN 00763862
Company Secretary15 Apr 20197 yrs 6 moSilicon Life Sciences Private Limited
Sapna
DIN 08434059
Director02 May 20197 yrs 6 moAurozymes Limited, Silicon Life Sciences Private Limited
Venkatanarayana Reddy Jayampu
DIN 08427188
Whole-time director23 May 20197 yrs 5 moApl Healthcare Limited
Jacob Joseph
DIN 08432306
Whole-time director23 May 20197 yrs 5 moSilicon Life Sciences Private Limited
Bhanu Murthy Chavali
DIN 08434178
Whole-time director27 May 20197 yrs 5 moCurepro Parenterals Limited
Sadananda Reddy Sannareddy
DIN 01815665
Director06 Aug 20206 yrs 3 moAurozest Private Limited
Girish Paman Vanvari
DIN 07376482
Director05 Nov 20206 yrsAurobindo Pharma Ltd
Suryanarayana Murthy Mula
DIN 07945899
CFO01 Jul 20215 yrs 4 moApl Healthcare Limited, Aurozest Private Limited, Silicon Life Sciences Private Limited
Santanu Mukherjee
DIN 07716452
Director09 Feb 20233 yrs 9 moAurobindo Pharma Ltd
Satakarni Makkapati
DIN 09377266
Director09 Nov 20233 yrsAurobindo Pharma Ltd
Mangalam Ramasubramanian Kumar
DIN 03628755
Director01 Apr 20242 yrs 7 moAurobindo Pharma Ltd
Mylandlahalli Rammohan Ashwini
DIN 10568862
Director17 May 20242 yrs 5 moApl Healthcare Limited
Punita Kumar Sinha
DIN 05229262
Director09 Feb 20269 moAurobindo Pharma Ltd

People of Aurobindo Pharma

13 people are tracked at Aurobindo Pharma (11 in leadership, 2 in team); the tracked headcount is 40,750.

NameRoleGroup
P V Ramprasad Reddy
Co-FounderLeadership
K Nityananda Reddy
Co-FounderLeadership
Sanjay Chaturvedi
CEOLeadership
Umesh K
Senior Vice President - Global Business OperationsLeadership
Ravikumar Pallinti
Vice President Projects and OperationsLeadership
Prasad Satam
Vice President - Packaging Research DevelopmentLeadership
Jamie Downey
Senior Director, DistributionLeadership
David Palew
Senior Director, US Supply ChainLeadership
Swami Iyer
CEO, North AmericaLeadership
Biren Shah
CFOLeadership
Srinivasa Marimganti
Vice PresidentLeadership
Chandrashekhar Kandi
SVP, R&D-FormulationsTeam
Amy Farris Wolfe
General CounselTeam
Premium access

Complete people profiles for Aurobindo Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Aurobindo Pharma

Aurobindo Pharma is a publicly listed company on the NSE with ticker symbol AUROPHARMA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date19 Jul 2000
  • Listed onNSE: AUROPHARMA
  • Listed entityAurobindo Pharma Ltd
  • Exchange sectorHealth technology
  • ISININE406A01037
  • Share price₹1,662.90 (-1.29% on the day) · 2026-10-14
  • Market capitalisation₹96,836 Cr
  • Price to earnings26.0
  • EPS (diluted, trailing year)₹64.00
  • Dividend yield0.24%
  • Volume (last session)899,369

Financials of Aurobindo Pharma

Exchange-reported figures of Aurobindo Pharma Ltd, the listed company behind Aurobindo Pharma (NSE: AUROPHARMA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹33,653 Cr
+6.1% YoY
EBITDA
₹6,780 Cr
+3.5% YoY
Profit After Tax
₹3,563 Cr
+3.2% YoY
Net Worth
₹37,896 Cr
+16.0% YoY
Total Assets
₹47,134 Cr
+14.2% YoY
Total Debt
₹8,068 Cr
-2.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue33,65331,72429,00224,85523,45524,77523,099
Revenue growth+6.1%+9.4%+16.7%+6.0%-5.3%+7.3%-
EBITDA6,7806,5515,6343,7074,1124,8434,823
EBITDA margin+20.2%+20.7%+19.4%+14.9%+17.5%+19.6%+20.9%
Profit before tax5,1125,0664,3802,6123,3737,3443,743
Net profit3,5633,4533,2731,9202,7573,4102,865
Net profit margin+10.6%+10.9%+11.3%+7.7%+11.8%+13.8%+12.4%
EPS (₹)60.3460.0254.1632.9045.2091.0548.56
Balance sheet
Total assets47,13441,26136,77632,35227,63827,51922,813
Net worth37,89632,65629,84326,84024,57621,93016,825
Total debt8,0688,2616,6485,2862,8515,3395,826
Cash & bank9,8708,2356,2786,0844,1905,4742,842
Net working capital20,90018,94215,78214,16111,87113,90310,590
Cash flow
Cash from operations5,5263,9252,4352,3875,0163,3294,381
Cash from investing(2,630)(1,866)(4,242)(3,971)(3,211)597(1,563)
Cash from financing(1,269)1208001,814(2,969)(1,365)(1,947)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue10,2639,1508,8538,6468,2867,8688,3827,979
Revenue growth (YoY)+23.9%+16.3%+5.6%+8.4%+6.3%+4.0%--
Other income168264117188122107135159
EBITDA2,1531,8391,7501,7081,6781,6031,7601,578
EBITDA margin+21.0%+20.2%+20.0%+19.9%+20.4%+20.6%+21.0%+20.0%
Depreciation531487479465429406444419
Interest10210298.2192.7795.2497.75115118
Profit before tax1,6881,5151,2911,3391,2761,2071,3351,200
Tax564483370429428383432354
Net profit1,1241,032921910848824903846
EPS (₹)19.5717.8615.8615.6714.6114.2015.5614.56
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue11,17210,93310,6468,45711,28715,82413,371
Revenue growth+2.2%+2.7%+25.9%-25.1%-28.7%+18.4%-
EBITDA3,0752,5582,2241,4901,3994,1202,698
EBITDA margin+27.5%+23.4%+20.9%+17.6%+12.4%+26.0%+20.2%
Profit before tax3,1642,3582,4571,6161,6374,1932,370
Net profit2,4271,7371,9511,2171,5363,1131,879
Net profit margin+21.7%+15.9%+18.3%+14.4%+13.6%+19.7%+14.1%
EPS (₹)41.5830.0833.3520.9424.8353.1332.03
Balance sheet
Total assets27,07625,23422,63022,32419,01719,95216,837
Net worth22,71820,53419,72318,03417,11715,92513,052
Total debt4,2854,6472,8614,2031,8954,0283,741
Cash & bank16229894.3437350.7838686.16
Net working capital5,1965,5124,8347,4477,4889,4458,646
Cash flow
Cash from operations2,9331,6461,7151,8163,7272,9942,201
Cash from investing(1,996)(2,050)(152)(3,230)(1,615)(2,650)(948)
Cash from financing(1,072)616(1,837)1,719(2,448)(27.94)(1,255)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3,1772,8002,7872,7472,7302,8482,7322,917
Revenue growth (YoY)+16.4%-1.7%+2.0%-5.8%-3.4%+15.8%--
Other income10324221413016083.7711454.26
Total expenses2,1921,9172,0051,9752,0092,0522,1352,203
EBITDA986882781772720796597713
EBITDA margin+31.2%+31.7%+28.4%+28.3%+26.7%+28.2%+21.9%+24.7%
Depreciation69.5268.9971.9371.9267.0070.0293.8868.28
Interest48.0947.0747.2748.4357.4460.0061.0966.19
Profit before tax9711,008876782756750556633
Tax247271184200174191147161

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue10,2639,1508,8538,6468,2867,8688,3827,979
Revenue growth (YoY)+23.9%+16.3%+5.6%+8.4%+6.3%+4.0%--
Other income168264117188122107135159
EBITDA2,1531,8391,7501,7081,6781,6031,7601,578
EBITDA margin+21.0%+20.2%+20.0%+19.9%+20.4%+20.6%+21.0%+20.0%
Depreciation531487479465429406444419
Interest10210298.2192.7795.2497.75115118
Profit before tax1,6881,5151,2911,3391,2761,2071,3351,200
Tax564483370429428383432354
Net profit1,1241,032921910848824903846
EPS (₹)19.5717.8615.8615.6714.6114.2015.5614.56
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue33,65331,72429,00224,85523,45524,77523,099
Revenue growth+6.1%+9.4%+16.7%+6.0%-5.3%+7.3%-
Other income4946225572914363,630192
Total expenses26,87325,17323,36821,14819,34419,93218,276
Employee cost5,1904,4763,9233,5223,4513,5353,219
EBITDA6,7806,5515,6343,7074,1124,8434,823
EBITDA margin+20.2%+20.7%+19.4%+14.9%+17.5%+19.6%+20.9%
Depreciation1,7781,6491,5221,2451,1271,055967
Interest38445729014048.6474.49305
Profit before tax5,1125,0664,3802,6123,3737,3443,743
Tax1,6091,5831,2116857262,010899
Net profit3,5633,4533,2731,9202,7573,4102,865
Net profit margin+10.6%+10.9%+11.3%+7.7%+11.8%+13.8%+12.4%
EPS (₹)60.3460.0254.1632.9045.2091.0548.56
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital62.6360.3558.5958.5958.5958.5958.59
Reserves & surplus37,83332,59529,78426,78124,51721,87116,766
Shareholders' funds (net worth)37,89632,65629,84326,84024,57621,93016,825
Minority interest(8.16)(6.39)8.0012.00(1.93)(0.88)0.14
Secured loans4,1193,9553,9682,5575441,0541,315
Unsecured loans3,9494,3062,6792,7292,3084,2864,511
Total debt8,0688,2616,6485,2862,8515,3395,826
Total liabilities47,13441,26136,77632,35227,63827,51922,813
Assets
Gross block29,25124,46323,44818,59315,52513,61312,441
Net block17,40714,79414,49311,02410,5329,3749,396
Capital work in progress5,2144,9003,8695,3903,7473,0621,986
Investments1,051252372543997591555
Inventories12,05310,5449,8108,5167,5599,0417,700
Sundry debtors7,0945,7464,8174,4664,0123,5034,315
Cash & bank balances9,8708,2356,2786,0844,1905,4742,842
Loans & advances2,9442,6372,8182,2471,9881,6601,555
Total current assets31,96227,16223,72421,31417,74919,67816,412
Total current liabilities11,0628,2207,9417,1535,8785,7755,823
Net working capital20,90018,94215,78214,16111,87113,90310,590
Total assets47,13441,26136,77632,35227,63827,51922,813
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash5,5643,3854,3924,1635,3272,7691,876
Net cash from operating activities5,5263,9252,4352,3875,0163,3294,381
Net cash from investing activities(2,630)(1,866)(4,242)(3,971)(3,211)597(1,563)
Net cash from financing activities(1,269)1208001,814(2,969)(1,365)(1,947)
Net change in cash1,6282,178(1,007)230(1,164)2,561871
Closing cash9,8708,2356,2786,0844,1905,4742,842
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.1%+9.4%+16.7%+6.0%-5.3%+7.3%-
EBITDA growth+3.5%+16.3%+52.0%-9.8%-15.1%+0.4%-
PBT growth+0.9%+15.7%+67.7%-22.5%-54.1%+96.2%+21.1%
Net income growth+3.2%+5.5%+70.5%-30.4%-19.2%+19.0%-
Revenue CAGR (3Y)+10.6%+10.6%+5.4%+2.5%+6.2%+14.6%+15.7%
EBITDA CAGR (3Y)+22.3%+16.8%+5.2%-8.4%+2.1%+8.7%+12.0%
Profitability & leverage
Net income margin+10.4%+11.0%+10.9%+7.8%+11.3%+21.5%+12.3%
Return on capital employed+12.4%+14.2%+13.5%+9.2%+12.4%+18.3%+18.5%
Return on net worth+9.9%+11.2%+11.2%+7.5%+11.4%+17.6%+18.5%
Debt / equity0.230.240.210.160.180.290.42
Long-term debt / equity0.040.070.060.030.020.020.01
Interest cover7.689.337.045.711.631.977.91
Efficiency & per share
Fixed asset turnover1.251.321.381.461.611.902.01
Inventory turnover2.983.123.173.092.832.963.09
Debtors turnover5.246.016.255.866.246.345.98
EPS (₹)60.3460.0254.1632.9045.2091.0548.56
Dividend per share (₹)4.000.004.507.509.004.003.00
Book value per share (₹)652.39562.21509.35458.10419.46374.29287.16
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3,1772,8002,7872,7472,7302,8482,7322,917
Revenue growth (YoY)+16.4%-1.7%+2.0%-5.8%-3.4%+15.8%--
Other income10324221413016083.7711454.26
Total expenses2,1921,9172,0051,9752,0092,0522,1352,203
EBITDA986882781772720796597713
EBITDA margin+31.2%+31.7%+28.4%+28.3%+26.7%+28.2%+21.9%+24.7%
Depreciation69.5268.9971.9371.9267.0070.0293.8868.28
Interest48.0947.0747.2748.4357.4460.0061.0966.19
Profit before tax9711,008876782756750556633
Tax247271184200174191147161
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue11,17210,93310,6468,45711,28715,82413,371
Revenue growth+2.2%+2.7%+25.9%-25.1%-28.7%+18.4%-
Other income588328670444671590389
Total expenses8,0978,3768,4226,9679,88811,70410,673
Employee cost1,1611,0639818911,6001,7351,577
EBITDA3,0752,5582,2241,4901,3994,1202,698
EBITDA margin+27.5%+23.4%+20.9%+17.6%+12.4%+26.0%+20.2%
Depreciation285297255243415488473
Interest21323018374.5816.9428.68243
Profit before tax3,1642,3582,4571,6161,6374,1932,370
Tax7496125033891831,080493
Net profit2,4271,7371,9511,2171,5363,1131,879
Net profit margin+21.7%+15.9%+18.3%+14.4%+13.6%+19.7%+14.1%
EPS (₹)41.5830.0833.3520.9424.8353.1332.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital58.0858.0858.5958.5958.5958.5958.59
Reserves & surplus22,66020,47619,66417,97517,05915,86612,994
Shareholders' funds (net worth)22,71820,53419,72318,03417,11715,92513,052
Secured loans1,9061,8421,4321,9232898421,314
Unsecured loans2,3802,8041,4292,2801,6063,1862,427
Total debt4,2854,6472,8614,2031,8954,0283,741
Total liabilities27,07625,23422,63022,32419,01719,95216,837
Assets
Gross block4,6334,2314,0436,2155,7256,8206,181
Net block2,5442,3372,4193,6883,5864,4724,418
Capital work in progress22987.53133239225735815
Investments17,56215,21013,3938,1056,5845,0102,527
Inventories2,3612,3592,3684,1253,3564,8414,360
Sundry debtors4,2104,1953,7774,5603,9735,9285,785
Cash & bank balances16229894.3437350.7838686.16
Loans & advances5638371,0019062,4551,0931,058
Total current assets7,2967,6897,2399,9659,83512,24911,288
Total current liabilities2,1002,1782,4062,5182,3472,8032,642
Net working capital5,1965,5124,8347,4477,4889,4458,646
Total assets27,07625,23422,63022,32419,01719,95216,837
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash29583.3235751.1338467.3568.70
Net cash from operating activities2,9331,6461,7151,8163,7272,9942,201
Net cash from investing activities(1,996)(2,050)(152)(3,230)(1,615)(2,650)(948)
Net cash from financing activities(1,072)616(1,837)1,719(2,448)(27.94)(1,255)
Net change in cash(135)212(274)306(335)316(1.35)
Closing cash16229894.3437350.7838686.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.2%+2.7%+25.9%-25.1%-28.7%+18.4%-
EBITDA growth+20.2%+15.0%+49.3%+6.5%-66.1%+52.7%-
PBT growth+34.1%-4.0%+52.1%-1.3%-61.0%+76.9%+20.6%
Net income growth+39.7%-11.0%+60.3%-20.8%-50.7%+65.7%-
Revenue CAGR (3Y)+9.7%-1.1%-12.4%-14.2%-2.7%+15.5%+11.7%
EBITDA CAGR (3Y)+27.3%+22.3%-18.6%-18.0%-16.6%+15.6%+4.4%
Profitability & leverage
Net income margin+21.6%+16.0%+18.4%+14.5%+12.9%+19.7%+14.0%
Return on capital employed+12.9%+10.8%+11.7%+8.2%+8.5%+23.0%+16.0%
Return on net worth+11.2%+8.7%+10.4%+7.0%+8.8%+21.5%+15.4%
Debt / equity0.210.190.190.170.180.270.34
Long-term debt / equity0.010.010.000.000.000.000.00
Interest cover7.6410.189.275.981.720.7910.94
Efficiency & per share
Fixed asset turnover2.522.642.081.421.802.432.30
Inventory turnover4.734.633.282.262.753.443.21
Debtors turnover2.662.742.551.982.282.702.43
EPS (₹)41.5830.0833.3520.9424.8353.1332.03
Dividend per share (₹)4.000.004.507.509.004.003.00
Book value per share (₹)391.14353.55336.62307.80292.15271.80222.78

Investments & Acquisitions by Aurobindo Pharma

Aurobindo Pharma has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Advent Pharma, GLS Pharma and Generis Farmaceutica.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Zentiva
Pharmaceutical products are manufactured and developed by Zentiva in Prague.
zentiva.comPrague, Czech Republic1958Aug 2025$5.5B
Tergene Biotech
Bio-conjugate technologies for bacterial vaccines and conjugates are developed.
tergene.comHyderabad, India2008Feb 2025••••
GLS Pharma
Oncology APIs and anti-cancer products are manufactured.
glspharma.comDelhi, India2004Jun 2022$3.6M
Veritaz Healthcare
Generic liquid and solid formulations are manufactured for pharmaceuticals.
veritaz.inHyderabad, India2005Mar 2022$22.49M
Advent Pharma
Specialty company developing therapeutics for treatment of respiratory diseases
advent-pharma.comScoresby, Australia2001Nov 2018••••
Generis Farmaceutica
Generic drugs for cardiovascular, neurological, and pain disorders are manufactured.
generis.ptAmadora, Portugal2002Jan 2017$142.79M
Natrol
Nutritional supplements are manufactured and marketed by Natrol.
natrol.comLos Angeles, United States1980Nov 2014$132.5M
Pharmacin
Nutritional supplements are manufactured by Pharmacin in the Netherlands.
pharmacin.nlZwijndrecht, Netherlands1986Dec 2006••••
Premium access

Complete acquisition details for Aurobindo Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Aurobindo Pharma

12 dated milestones of Aurobindo Pharma across 39 years, from founding to its latest funding, stage changes and deals.

  1. Founded Aurobindo Pharma is founded.
  2. Funding First funding round of $6.2M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Pharmacin.
  5. Acquisition Acquires Natrol.
  6. Acquisition Acquires Generis Farmaceutica.
  7. Funding Latest funding round, Post-IPO,.
  8. Acquisition Acquires Advent Pharma.
  9. Acquisition Acquires Veritaz Healthcare.
  10. Acquisition Acquires GLS Pharma.
  11. Acquisition Acquires Tergene Biotech.
  12. Acquisition Acquires Zentiva.

Competitors of Aurobindo Pharma

Aurobindo Pharma has 3 listed competitors in our database, 1 of them funded. They include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Indoco Remedies
indoco.com1947Mumbai, India6,291
APIs manufacturing and formulation services are provided in therapeutic segments.
Concord Biotech
concordbiotech.com2000Ahmedabad, India1,598
APIs and enzymes are manufactured through fermentation by the CDMO.
BDR Pharmaceuticals Internationals
bdrpharma.com2003Mumbai, India$88.16M1,864
APIs and finished products are developed and manufactured.
Premium access

Detailed competitors of Aurobindo Pharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Aurobindo Pharma

The website of Aurobindo Pharma (aurobindo.com) receives about 24.4K visits a month.

  • Monthly visits
    24.4K

    ▲ 3.7% vs previous month

Similar websites

Websites whose visitors overlap most with Aurobindo Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Natco Pharma
natcopharma.co.in
100%
19.8K#1,133,324View details
Dr. Reddy's Laboratories
drreddys.com
98%
118.8K#308,607View details
B. Braun
bbraun.com
95%
326.1K#144,841View details
Bristol-Myers Squibb
bms.com
94%
809.8K#67,210View details
cardinal.com
cardinal.com
94%
#8,784,623–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Aurobindo Pharma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Aurobindo Pharma (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Aurobindo Pharma

Aurobindo Pharma: CLSA on Aurobindo Pharma maintains Hold, Target Price Rs 1800; The company reported record revenue and EBITDA, supported by healthy growth across geographies, while margins improved 75bps YoY. US revenue benefited from the Lannett acquisition. Management retained its FY27 guidance of double-digit revenue growth and margins above 21%, with FY28 expected to benefit from a full-year Lannett contribution and new biosimilar launches.
Exchange Update • 4 days ago
Aurobindo Pharma: Citi on Aurobindo Pharma maintains Sell, Target Price Rs 1270; Q2FY27 EBITDA and PAT beat estimates by 8% and 9%, respectively, driven by 19% constant-currency growth in Europe, better-than-expected US traction and currency tailwinds. US sales rose 20% QoQ to US$477mn, largely due to the Lannett consolidation, while EBITDA margin remained flat at 21%. Citi remains cautious about the sustainability of European growth amid market saturation and pricing pressure.
Exchange Update • 5 days ago
Aurobindo: China Facility Likely To Achieve Break-Even By The Q3 Of Fiscal Year 2027.
Exchange Update • 5 days ago
Aurobindo: Aims for 12,000 Tons of Peng Production by FY28, Up from Approximately 10,000 Tons Now, and Has Filed Anti-Dumping Under Government Rules.
Exchange Update • 5 days ago
Aurobindo: Expects FY28 To Surpass FY27 Due To Full Contributions From Lannett, Increased Production In China, And Growth In Biosimilars.
Exchange Update • 5 days ago
AUROPHARMA: RS. 52.08 CRORES BSE BLOCK TRADE; FOR ~ 300,000 SHARES, AT RS. 1736.00
Exchange Update • 5 days ago
AUROPHARMA: Q2 REVENUE 102.63B RUPEES VS 82.85B (YOY)
Exchange Update • 6 days ago
AUROPHARMA: Q2 CONS NET PROFIT 11.26B RUPEES VS 8.5B (YOY); EST 11.3B
Exchange Update • 6 days ago
AUROPHARMA: Q2 EBITDA 22.9B RUPEES VS 16.8B (YOY); Q2 EBITDA MARGIN 22.37% VS 20.25% (YOY)
Exchange Update • 6 days ago
Aurobindo Pharma shares hit 52-week high on final USFDA approval for Perampanel tablets
Moneycontrol • 1 month ago
Premium access

Complete news archive for Aurobindo Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Aurobindo Pharma on our blog

Frequently Asked Questions about Aurobindo Pharma

Aurobindo Pharma was founded in 1986 and raised its 1st funding round 13 years after it was founded.

Aurobindo Pharma is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Sanjay Chaturvedi is the CEO of Aurobindo Pharma, as recorded in our data.

Aurobindo Pharma has 40,750 employees.

The primary company behind Aurobindo Pharma, Aurobindo Pharma Ltd, reported revenue of ₹34,147 Cr for FY 2026, up 6% year on year.

Aurobindo Pharma was founded in 1986 in Hyderabad, India, and operates within the pharmaceutical sector. Generic drugs and biocatalytic solutions are developed and manufactured by the company, with a focus on active pharmaceutical ingredients and formulations. Operations are conducted globally, serving markets in over 150 countries through exports and partnerships. Leadership is provided by co-founders P V Ramprasad Reddy and K Nityananda Reddy, alongside CEO Sanjay Chaturvedi.

Aurobindo Pharma's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Indoco Remedies.

Aurobindo Pharma offers APIs, Biosimilars, and Speciality Products.

Yes, Aurobindo Pharma is publicly traded on NSE under the ticker symbol AUROPHARMA.

Aurobindo Pharma has made 8 acquisitions, including Advent Pharma, GLS Pharma, and Generis Farmaceutica.

Aurobindo Pharma has 2 investors. Key investors include Gates Foundation, and Templeton Private Equity Partners.

Aurobindo Pharma is associated with 6 legal entities: Aurobindo Pharma Ltd, Apl Healthcare Limited, Curepro Parenterals Limited and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available